The medical tubing industry sits quietly behind almost every modern healthcare procedure — from IV lines and catheters to drug-delivery systems and diagnostic equipment. Every time a patient receives an infusion, undergoes a minimally invasive surgery, or is connected to a monitoring device, medical tubing is doing the unglamorous but essential work of moving fluids, gases, and instruments safely through the body. It's not a flashy corner of medtech, but it's a fast-growing one, propelled by an aging population, rising rates of chronic disease, and steady innovation in the polymers and manufacturing processes behind these products:

• Market Size, 2025: $12.9 billion
• Market Estimate, 2026: $13.9 billion
• Market Forecast, 2033: $25.5 billion
• CAGR, 2026–2033: 9.0%

That growth is being driven by an aging global population, a rise in chronic disease, and a wave of consolidation among the companies that make the tubes themselves.

Here's a closer look at what's fueling the market, which materials are winning, and how key players are maneuvering through acquisitions to stay ahead.

Key Drivers and Material Trends

An aging, sicker population is driving volume. The single biggest force behind market growth is demographic. As the global geriatric population expands, so does demand for the medical devices that depend on tubing — catheters, feeding tubes, and drug-delivery systems chief among them. In the U.S. alone, the population aged 65 and older is projected to nearly double from 52 million in 2018 to 95 million by 2060, and that trend is echoed across most developed healthcare markets. Layered on top of this is a rising incidence of cardiovascular disease, cancer, and arthritis — conditions that increasingly require complex surgical or minimally invasive procedures, most of which rely on tubing-equipped instruments.

Minimally invasive procedures are pushing material innovation. As hospitals shift toward less invasive treatment methods, demand has grown for tubing made from nylon, silicone, and specialty plastic polymers — materials suited to the fine tolerances and biocompatibility that catheters and similar devices require.

PVC still leads, but its dominance is under pressure. Polyvinyl chloride (PVC) remains the largest product segment by revenue, holding roughly 30.7% share in 2023. It's cheap, easy to sterilize (via irradiation or ethylene oxide), and well suited to the disposable, single-use devices that now dominate clinical settings. But PVC's future isn't guaranteed — its traditional formulation relies on the plasticizer DEHP, a compound facing growing regulatory scrutiny for toxicity. Manufacturers are responding by shifting toward DEHP-free PVC formulations, a transition expected to define much of the product's next growth phase.

Silicone is the material to watch. Increasingly favored for catheters and bulk disposable tubing, silicone offers a combination of properties that's hard to beat clinically: it's latex-free (a major plus for patients with latex sensitivities), highly flexible, resistant to extreme temperatures, and less prone to encrustation than older materials. It's manufactured through a continuous vulcanization and extrusion process that yields a higher, more consistent medical grade than standard silicone products.

Fluoropolymers are the fastest-growing niche. Materials like PTFE and FEP are inert, non-toxic, and easily sterilized, making them the material of choice for next-generation devices — sutures, biocontainment vessels, syringes, and advanced catheters. As device makers push toward more sophisticated, miniaturized designs, fluoropolymer tubing is positioned to be one of the fastest-growing product categories through 2030.

Extrusion technology is quietly changing the economics. Advances in extrusion — including braided, tapered, and para tubing — allow manufacturers to produce complex tubing geometries in a single pass, eliminating the need to join multiple tube segments. That cuts secondary manufacturing steps and lowers costs, while also enabling combinations of flexibility, tensile strength, and light weight that weren't previously possible in a single product.

Want the full data behind these numbers? Download a free sample of the Medical Tubing Market report

Prominent Industry Trends

Bulk disposable tubing leads application demand. This segment — which covers urological products, surgical instruments, syringes, and needles — accounted for 34.5% of application revenue in 2023, driven largely by infection-control priorities in hospital settings. The push toward single-use, disposable components shows no sign of slowing.

Catheters remain a structural growth engine. As chronic disease prevalence rises and more procedures shift toward minimally invasive approaches, catheter demand continues to climb — with silicone and PVC as the dominant materials of choice.

Regional demand is bifurcated. North America led the market with a 35.5% revenue share in 2023, propelled by high healthcare spending (U.S. Medicare spending rose 8.4% to $900 billion in 2021, per National Health Expenditure data) and a dense base of established manufacturers. But Asia Pacific is the fastest-growing region, as healthcare infrastructure improves, geriatric populations expand, and manufacturers race to make advanced medical products more accessible across the region.

Reshoring and localized production are gaining traction. In a notable example, Freudenberg expanded its medical tubing production into Massachusetts in February 2023, specifically to serve Eastern U.S. customers with custom, localized solutions — a sign that manufacturers are increasingly building regional capacity rather than relying solely on centralized production.

Key Players and MA Activity

The competitive landscape is populated by a mix of diversified industrial conglomerates and specialized medical extrusion firms, including Saint-Gobain, Freudenberg Co. KG, Nordson Corporation, TE Connectivity, Trelleborg AB, Spectrum Plastics Group, Zeus Industrial Products, W. L. Gore Associates, The Lubrizol Corporation, NewAge Industries, and Hitachi Cable America, among others.

Consolidation has become the dominant strategic playbook in this space, as larger players acquire specialized manufacturers to expand technical capabilities and geographic reach:

• Nordson Corporation acquired Atrion Corporation (August 2024) — a move into medical infusion and cardiovascular solutions that broadened Nordson's precision-technology portfolio and gave it a stronger foothold in higher-complexity medical devices.
• Arterex acquired Xponent Global Inc. (July 2025) — an extrusion specialist bringing over 80 years of combined industry experience, additional extrusion lines, and ISO Class 8 cleanroom capabilities, strengthening Arterex's position in multi-lumen and precision tubing.
• Lubrizol expanded its distribution partnership with IMCD (June 2025) — extending an existing European collaboration into North America to widen access to Lubrizol's medical-grade thermoplastic polyurethane (TPU) portfolio.
• Nordson's earlier acquisition of Fluortek rounded out its fluoropolymer tubing capabilities, reflecting the broader industry shift toward high-performance materials.

These deals share a common logic: rather than building new capabilities organically, manufacturers are buying specialized extrusion expertise, cleanroom capacity, and material science know-how to keep pace with medtech's growing complexity. Expect this pattern — large industrial players absorbing niche extrusion and materials specialists — to continue as demand for precision, biocompatible tubing accelerates through the end of the decade.

The Bottom Line

Medical tubing may not be a headline-grabbing category, but it's a market experiencing the same forces reshaping healthcare more broadly: an aging population, a shift toward minimally invasive care, tightening material regulations, and a wave of consolidation among suppliers racing to keep up. Companies that can pair advanced materials — like silicone and fluoropolymers — with efficient, high-precision manufacturing are best positioned to capture growth as the market approaches $20 billion by the end of the decade.

Need data cut your way? Request free report customization by product, application, or region